high5md

Concise and in-depth coverage of the most important conferences in the field of oncology and immunology on &

[high5md @high5md]

🎥 Behind the scenes at EULAR 2026 in London!

While the latest breakthroughs in rheumatology and immunology are being presented at the congress, our team is already hard at work behind the camera. Together with leading international experts, we are presenting the most exciting study results, key congress highlights, and their relevance for clinical practice.

Stay tuned for concise congress summaries, expert perspectives, and the most important take-home messages from EULAR 2026.

📅 Available June 6th 2026, free of charge, on https://t.co/L9MX6UyiTJ – exclusively for healthcare professionals.

#EULAR2026 #EULAR #Rheumatology #Immunology #AutoimmuneDiseases #ClinicalTrials #PrecisionMedicine #MedicalEducation #ImmunologyResearch #high5immunologyTV

[high5md @high5md]

All high5oncologyTV ASCO 2026 reports are now available on demand.

🎥 Expert coverage of:
• Breast Cancer
• GU Oncology
• Lung Cancer

✅ Free access
✅ On demand
✅ For healthcare professionals

Watch now:
https://t.co/pbS79Fdlmj

#ASCO26 #Oncology #high5oncologyTV

[high5md @high5md]

The first reports from our high5oncologyTV ASCO 2026 coverage are now live.

🎥 Expert analysis on:
• Breast Cancer
• GU Cancers
• Lung Cancer

✅ Free
✅ On demand
✅ Directly from Chicago

Watch now and stay up to date with the latest ASCO 2026 data: https://t.co/4PJw1aT9bW
#ASCO26 #Oncology #high5oncologyTV

[OncoAlert @OncoAlert]

The OncoAlert🚨 Lung faculty’s TOP 10 abstracts In Thoracic🫁 Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior #LungCancer experts across #NSCLC & #SCLC .
A snapshot of what will shape LUNG oncology at #ASCO26 👇

🔹 HARMONI-6 — Ivonescimab + chemo vs tislelizumab + chemo in sqNSCLC (OS, Ph3)
🔹 LIBRETTO-432 — Adjuvant selpercatinib in RET+ NSCLC (EFS, Ph3)
🔹 WU-KONG28 — Sunvozertinib vs chemo in EGFR Ex20ins NSCLC (Ph3)
🔹 OPTITROP-LUNGO5 — Sac-TMT + pembrolizumab in PD-L1+ NSCLC (Ph3)
🔹 TRITON — Tremelimumab/durvalumab/chemo in STK11/KEAP1/KRAS-mut NSCLC
🔹 CROWN 7-year update — Lorlatinib vs crizotinib in ALK+ NSCLC
🔹 LORIN — Neoadjuvant lorlatinib in stage III ALK+ NSCLC
🔹 ACCELERET-LUNG — 1L pralsetinib in RET+ NSCLC
🔹 Silevertinib (BDTX-1535) — Non-classical EGFR-mut NSCLC
🔹 Concurrent CRT + durvalumab in ES-SCLC (Phase III)

Leads
@HHorinouchi
@UOzkerim
@WeOncologists

Senior Faculty
@GlopesMd
@StephenVLiu
@peters_solange
@CharuAggarwalMD
@MartinReck2
@christine_lovly

Participating AF
@DrMirallas

Pinging faculty
@bmassutis @UmbertoMalapel1
@jillfeldman4 @bensolomon1 @VanitaNoronha @DrSanjayPopat @DrJNaidoo
@Latinamd @JulienMazieres @TerriConneran @BRicciutiMD

[OncoAlert @OncoAlert]

The OncoAlert🚨 GU faculty’s TOP 10 abstracts In GU Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior GU cancer experts across #ProstateCancer #KidneyCancer #BladderCancer .
A snapshot of what will shape GU oncology at #ASCO26 👇

1️⃣ LBA5007 — TALAPRO-3
Talazoparib + enzalutamide vs placebo + enzalutamide in mCSPC with HRR alterations

2️⃣ LBA1 — PROTEUS
Perioperative apalutamide + ADT vs ADT in high-risk localized/locally advanced prostate cancer (final Phase 3)

3️⃣ 5001 — ENZAMET genomic analysis
Decipher >0.85 to identify benefit from adding docetaxel to ADT + enzalutamide

4️⃣ LBA4511 — KEYNOTE-564 ctDNA
ctDNA dynamics in RCC treated with adjuvant pembrolizumab vs placebo

5️⃣ 4502 — RAMPART
Durvalumab vs active monitoring after resection in RCC (Phase 3 RCT)

6️⃣ 4500 — RADICAL (A031801)
Radium-223 + cabozantinib in RCC with bone metastases

7️⃣ 4507 — EV-302 long-term follow-up
Enfortumab vedotin + pembrolizumab vs chemotherapy in 1L LA/mUC

8️⃣ 4513 — AMBASSADOR (A031501)
HRQoL with adjuvant pembrolizumab vs observation in high-risk MIBC

9️⃣ 4503 — SAKK 06/19
Perioperative intravesical rBCG + chemo-IO strategy in MIBC (primary analysis)

🔟 4510 — KEYNOTE-905
HRQoL with perioperative enfortumab vedotin + pembrolizumab in cisplatin-ineligible MIBC

Leads
@nataliagandur
@scocmem
@AmandaNizamMD
@WeOncologists

Senior Faculty
@montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @Silke_Gillessen
@tompowles1 @AndreaNecchi @cdanicas @AOmlin

Pinging
@crisbergerot @HHammersMD @ravikanesvaran @sonpavde @drenriquegrande @scserendipity1 @EfstathiouEleni @BraunMDPhD @brian_rini

[OncoAlert @OncoAlert]

🚨 The OncoAlert #BreastCancer faculty’s TOP 10 abstracts for #ASCO26 — selected by our leads and finalized through a Delphi voting process with senior breast cancer experts.

1️⃣ 500 — OPTIMA
Test-directed chemotherapy in high-risk ER+/HER2- early BC
2️⃣ LBA1006 — PERSEVERA BC
Giredestrant + palbociclib vs letrozole + palbociclib in 1L ER+/HER2- LA/MBC
3️⃣ 507 — KEYNOTE-522 final analysis
Perioperative pembrolizumab in high-risk early TNBC
4️⃣ LBA1007 — SERENA-6
1L camizestrant for emergent ESR1 mutations — final PFS2
5️⃣ 502 — LIDERA BC
Giredestrant in ER+/HER2- early BC by menopausal status
6️⃣ LBA1000 — ASCENT-04
SG + pembrolizumab vs chemo + pembrolizumab in 1L PD-L1+ mTNBC
7️⃣ 501 — NATALEE biomarker analysis
Baseline gene expression and adjuvant ribociclib benefit
8️⃣ LBA503 — SENOMAC
Omission of axillary dissection: OS + arm morbidity
9️⃣ 1001 — ASCENT-03
SG vs chemotherapy in 1L mTNBC — PFS2
🔟 LBA1003
Izalontamab brengitecan vs physician’s choice chemo in metastatic TNBC

Leads🚨
@ElisaAgostinett
@to_be_elizabeth
@WeOncologists

Senior Faculty
@ErikaHamilton9
@E_de_Azambuja
@matteolambe
@DrSGraff
@hoperugo
@BianchiniGP
Dr. Bidard
@Icro_Meattini

Participating AF
@Lucarecco
@GaiaGriguolo

Ping Faculty
@aftimosp @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @teamoncology @stolaney1 @LoiSher @SirohiBhawna @chemobrainfog @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @paspears88 @MammaMiaMagazin @itrisabel

[high5md @high5md]

🎥 Leading international IBD experts united at the 5 Nations in IBD Meeting in Toledo.

A huge thank you to all specialists who joined high5immunologyTV to share their perspectives, clinical insights, and the latest developments in IBD care.

Watch all expert interviews and meeting highlights free and on demand: https://t.co/5z8g4urcAl

@alearmuzzi @manu_barreiro @yzabanaa @AngelaVariola @EdoSavarino @HenitYanaiMD @Max_Fantini @HelenaTavaresdS @IborraMarisa @CalafatSard
@PGetaid @GEDII_IBD @geteccu @IGIS_ibd @IGIBD1

#5NationsIBD #IBD #Gastroenterology #5N #MedicalEducation #CrohnsDisease #UlcerativeColitis #Immunology

[high5md @high5md]

The 5 Nations Meeting in IBD starts today in Toledo — and the #high5immunologyTV team is live on site to bring you the latest expert insights and highlights from the meeting.

🎥 Full coverage will be available free and on demand starting Monday, May 25. Stay tuned!

#5NationsIBD #IBD #Gastroenterology #InflammatoryBowelDisease #MedicalEducation

[high5md @high5md]

Recent weeks have brought important momentum in oncology, including several FDA approvals across different tumor types.
👉 Swipe for a concise overview of current and clinically relevant developments!
#Oncology #Hematology #ProstateCancer #OvarianCancer #MultipleMyeloma

[high5md @high5md]

Upgrade your clinical tool kit with the updated high5 breast cancer app: all information from diagnosis, therapy algorithm to management of adverse effects. Developed by leading experts in the field – free download for all HCPs.

Download now for free: https://t.co/hUqpGXdtRy

#BreastCancer #Oncology #EvidenceBasedMedicine #DigitalHealth #oncology #high5md

[high5md @high5md]

Missed ASCO GU 2026? We’ve got you covered.

If you couldn’t attend in person, you don’t have to miss out on the key insights: The highlights from ASCO GU 2026 are now available on demand and free of charge on high5oncologyTV.

Concise, clinically relevant, and accessible anytime – exclusively for healthcare professionals.

👉 Register now for free and start watching: https://t.co/r6JE1zCViC

#ASCOGU2026 #GUOncology #Oncology #MedicalEducation #MedEd

[high5md @high5md]

ASCO GU 2026 – the latest data in just 100 seconds!

Our on-site experts present the newest insights from ASCO GU 2026 – concise, clinically relevant, and straight to the point.
Stay up to date in genitourinary oncology in no time – on demand and free of charge on high5oncologyTV.

👉 Register now and get the most important results in 100 seconds: https://t.co/r6JE1zCViC

#ASCOGU2026 #GUOncology #Oncology #MedicalEducation #MedEd

[high5md @high5md]

⏱️ ASCO GU 2026 is just around the corner!
Stay tuned for exclusive congress highlights and expert discussions – bringing you the latest insights directly from the meeting.

On high5oncologyTV, you’ll be close to the most important new developments in genitourinary oncology.

👉 Register now for free and don’t miss out! https://t.co/r6JE1zCViC

#ASCOGU2026 #GUOncology #Oncology #MedicalEducation #Healthcare #MedEd

[high5md @high5md]

ECCO 2026 has come to an end – but the insights and discussions continue.
On our website, you can now explore our full coverage, including exclusive expert videos, key takeaways, and in-depth analyses. Don’t miss the opportunity to catch up on the highlights!
A special thank you to all the experts for the excellent collaboration and for the engaging and lively discussions captured in our videos.

🖥️ Visit our website https://t.co/L9MX6UyiTJ and watch the content now!
#ECCO2026 #MedEd #IBD #ColitisUlcerosa #CrohnsDisease

[high5md @high5md]

Couldn’t join ECCO 2026 in person? We’ve got you covered. 
Our international experts discussed on how pathway-targeted therapies may reshape treatment strategies, how precision medicine is evolving towards more dynamic, data-driven decision-making, and how earlier intervention concepts and anti-fibrotic strategies could impact long-term disease control.

🔎 Watch the highlights now on https://t.co/L9MX6UyiTJ!
#ECCO2026 #IBD #Immunology #PrecisionMedicine #MedicalEducation

[high5md @high5md]

Our content from the ECCO Congress 2026 in Stockholm is now available!
Explore concise summaries, the latest study data and practical expert insights from IBD.

💻 Watch now for free on https://t.co/1B0PQ61RfR

[high5md @high5md]

🗓️ Only a few days to go until #ECCO2026!
Look forward to concise 100-second video updates and expert discussions covering the latest advances in IBD management — evidence-based, clinically relevant and to the point.
Register for free at https://t.co/B2U4TlQCrw to stay ahead and make sure you don’t miss any highlights!
#ECCO #IBD #Gastroenterology #Immunology #MedEd

[high5md @high5md]

🎓 #ASH2025 – new expert discussions
From indolent and aggressive non-Hodgkin lymphoma and CLL/SLL to treatment strategies in NDMM, r/r MM and the latest advances in CAR T-cell therapy.
👉 Watch now on https://t.co/vv4rOL99G1
#Hematology #Oncology #Lymphoma #MultipleMyeloma #CARTcell

With special thanks to our complete expert panel:
@tobyeyre82, @MJerkeman, @H_Einsele, @hhashmi87, @LipeBrea, @MyelomaOslo, Martin Dreyling, Simone Ferrero, Catherine Thieblemont, Clementine Sarkozy, Maximilian Merz

[high5md @high5md]

🔍 Key insights at a glance
The ASH meeting in Orlando is behind us – once again delivering pivotal impulses for hematology:
➡️ exciting new clinical trial data on leukemias, lymphomas & multiple myeloma
➡️ advances in innovative therapeutic approaches
➡️ practice-relevant updates for everyday clinical care

Find in-depth coverage and expert insights on https://t.co/vv4rOL99G1 – free of charge for medical professionals.
🎓 Stay informed and don’t miss what matters!
#ASH2025 #Hematology #Oncology #CongressUpdate #ClinicalHighlights #MedicalEducation